Cargando…
Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
PURPOSE: Ranibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) (central RVO (CRVO) and branch RVO (BRVO)). Their real-world usage, however, has yet to be compa...
Autores principales: | Nghiem-Buffet, S, Baillif, S, Regnier, S, Skelly, A, Yu, N, Sodi, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395996/ https://www.ncbi.nlm.nih.gov/pubmed/27911446 http://dx.doi.org/10.1038/eye.2016.269 |
Ejemplares similares
-
Comparison of Intravitreal Dexamethasone Implant and Intravitreal Ranibizumab Efficacy in Younger Patients with Branch Retinal Vein Occlusion
por: Ozcift, Seda Gurakar, et al.
Publicado: (2023) -
Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion
por: Liang, Xuemei, et al.
Publicado: (2022) -
Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017) -
Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
por: Dogan, Emine, et al.
Publicado: (2018) -
A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion
por: Bandello, Francesco, et al.
Publicado: (2018)